Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913612 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT02913612 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 105 participants.
The verdict
NCT02913612, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.
Interventions
- DRUG 0.25% Timolol Maleate Gel Forming Solution
- DRUG 0.5% Timolol Maleate Gel Forming Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2020-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02913612
The ClinicalTrials.gov registry entry for NCT02913612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanecia Obie Zimmerman, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.25% Timolol Maleate Gel Forming Solution is the first listed.
NCT02913612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02913612 about?
NCT02913612 is a clinical study titled "Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)". The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.
What is the current status of trial NCT02913612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2017-05-05. Estimated completion is 2020-10-20.
What interventions are being tested in trial NCT02913612?
The interventions under investigation include: 0.25% Timolol Maleate Gel Forming Solution (DRUG), 0.5% Timolol Maleate Gel Forming Solution (DRUG).
Who is sponsoring clinical trial NCT02913612?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.